Suicide gene and cytokines combined nonviral gene therapy for spontaneous canine melanoma

Cancer Gene Therapy

Volumn 15, Issue 3, 2008, Pages 165-172

  Finocchiaro, L M E ^a   Fiszman, G L ^a   Karara, A L ^a   Glikin, G C ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

DMRIE; Ganciclovir; GM CSF; HSV TK; IL 2; Lipofection

Indexed keywords

1,2 DIMYRISTYLOXYPROPYL 3 DIMETHYLHYDROXYETHYLMONIUM BROMIDE; 1,2 DIOLEOYLGLYCERO 3 PHOSPHATIDYLETHANOLAMINE; ACICLOVIR; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; LIPOPLEX; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER SURVIVAL; CELL INFILTRATION; CELL SECRETION; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE FREE SURVIVAL; DOG DISEASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FISHER EXACT TEST; HERPES SIMPLEX; IMMUNOCOMPETENT CELL; IRRADIATION; KAPLAN MEIER METHOD; LIPOSOMAL GENE DELIVERY SYSTEM; MALE; MELANOMA; METASTASIS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; SUICIDE GENE THERAPY; SURVIVAL TIME; TOXICITY; TRANSGENE; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; CYTOKINES; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GANCICLOVIR; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-2; MALE; MELANOMA; SIMPLEXVIRUS; SURVIVAL ANALYSIS; THYMIDINE KINASE;

HERPES; SIMPLEXVIRUS;

EID: 39049164835     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7701096     Document Type: Article

References (33)

1. Hansen K, Khanna C. Spontaneous and genetically engineered animal models; use in preclinical cancer drug development. Eur J Cancer 2004; 40: 858-880.
2. Ramos-Vara JA, Beissenherz ME, Miller MA, Johnson GC, Pace LW, Fard A et al. Retrospective study of 338 canine oral melanomas with clinical, histologic, and immunohistochemical review of 129 cases. Vet Pathol 2000; 37: 597-608.
3. Smith SH, Goldschmidt MH, McManus PM. A comparative review of melanocytic neoplasms. Vet Pathol 2002; 39: 651-678.
4. Dow SW, Elmslie RE, Willson AP, Roche L, Gorman C, Potter TA. In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. J Clin Invest 1998; 101: 2406-2414.
5. Quintin-Colonna F, Devauchelle P, Fradelizi D, Mourot B, Faure T, Kourilsky P et al. Gene therapy of spontaneous canine melanoma and feline fibrosarcoma by intratumoral administration of histoincompatible cells expressing human interleukin-2. Gene Therapy 1996; 3: 1104-1112.
6. Hogge GS, Burkholder JK, Culp J, Albertini MR, Dubielzig RR, Keller ET et al. Development of human granulocyte-macrophage colony-stimulating factor-transfected tumor cell vaccines for the treatment of spontaneous canine cancer. Hum Gene Ther 1998; 9: 1851-1861.
7. Bergman PJ, McKnight J, Novosad A, Charney S, Farrelly J, Craft D et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 2003; 9: 1284-1290.
8. Bianco SR, Sun J, Fosmire SP, Hance K, Padilla ML, Ritt MG et al. Enhancing antimelanoma immune responses through apoptosis. Cancer Gene Ther 2003; 10: 726-736.
9. Clark PR, Stopeck AT, Ferrari M, Parker SE, Hersh EM. Studies of direct intratumoral gene transfer using cationic lipid-complexed plasmid DNA. Cancer Gene Ther 2000; 7: 853-860.
10. Aghi M, Hochberg F, Breakefield XO. Prodrug activation enzymes in cancer gene therapy. J Gene Med 2000; 2: 148-164.
11. Tomicic MT, Thust R, Kaina B. Ganciclovir-induced apoptosis in HSV-1 thymidine kinase expressing cells: critical role of DNA breaks, Bcl-2decline and caspase-9 activation. Oncogene 2002; 21: 2141-2153.
12. Mesnil M, Yamasaki H. bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res 2000; 60: 3989-3999.
13. San H, Yang ZY, Pompili VJ, Jaffe ML, Plautz GE, Xu L et al. Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy. Hum Gene Ther 1993; 4: 781-788.
14. Rochlitz C, Dreno B, Jantscheff P, Cavalli F, Squiban P, Acres B et al. Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels. Cancer Gene Ther 2002; 9: 289-295.
15. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411: 380-384.
16. Dranoff G. GM-CSF-based cancer vaccines. Immunol Rev 2002; 188: 147-154.
17. Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 1998; 95: 13141-13146.
18. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994; 264: 961-965.
19. Jaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, Sauter PR et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001; 19: 145-156.
20. Pan PY, Li Y, Li Q, Gu P, Martinet O, Thung S et al. In situ recruitment of antigen-presenting cells by intratumoral GM-CSF gene delivery. Cancer Immunol Immunother 2004; 53: 17-25.
21. Chen SH, Kosai K, Xu B, Pham-Nguyen K, Contant C, Finegold MJ et al. Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res 1996; 56: 3758-3762.
22. Bonnekoh B, Greenhalgh DA, Chen SH, Block A, Rich SS, Krieg T et al. Ex vivo and in vivo adenovirus-mediated gene therapy strategies induce a systemic anti-tumor immune defence in the B16 melanoma model. J Invest Dermatol 1998; 110: 867-871.
23. Guo SY, Gu QL, Zhu ZG, Hong HQ, Lin YZ. TK gene combined with mIL-2 and mGM-CSF genes in treatment of gastric cancer. World J Gastroenterol 2003; 9: 233-237.
24. Majumdar AS, Zolotorev A, Samuel S, Tran K, Vertin B, Hall-Meier M et al. Efficacy of herpes simplex virus thymidine kinase in combination with cytokine gene therapy in an experimental metastatic breast cancer model. Cancer Gene Ther 2000; 7: 1086-1099.
25. Brockstedt DG, Diagana M, Zhang Y, Tran K, Belmar N, Meier M et al. Development of anti-tumor immunity against a non-immunogenic mammary carcinoma through in vivo somatic GM-CSF, IL-2, and HSVtk combination gene therapy. Mol Ther 2002; 6: 627-636.
26. Kaufman RJ, Davies MV, Wasley LC, Michnick D. Improved vectors for stable expression of foreign genes in mammalian cells by use of the untranslated leader sequence from EMC virus. Nucleic Acids Res 1991; 19: 4485-4490.
27. Casais CC, Karara AL, Glikin GC, Finocchiaro LME. Effects of Spatial Configuration on Tumor Cells Transgene Expression. Gene Ther Mol Biol 2006; 10: 207-222.
28. Finocchiaro LME, Bumaschny VF, Karara AL, Fiszman GL, Casais CC, Glikin GC. Herpes simplex virus thymidine kinase/ ganciclovir system in multicellular tumor spheroids. Cancer Gene Ther 2004; 11: 333-345.
29. Gao X, Huang L. Cationic liposome-mediated gene transfer. Gene Therapy 1995; 2: 710-722.
30. Ramesh R, Munshi A, Abboud CN, Marrogi AJ, Freeman SM. Expression of costimulatory molecules: B7 and ICAM up-regulation after treatment with a suicide gene. Cancer Gene Ther 1996; 3: 373-384.
31. Li XL, Boyanapalli M, Weihua X, Kalvakolanu DV, Hassel BA. Induction of interferon synthesis and activation of interferon-stimulated genes by liposomal transfection reagents. J Interferon Cytokine Res 1998; 18: 947-952.
32. Roman M, Martin-Orozco E, Goodman JS, Nguyen MD, Sato Y, Ronaghy A et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997; 3: 849-854.
33. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 1997; 186: 1623-1631.